Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Leleu

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Bone Marrow Transplantation|September 22, 2019
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)E González-Barca, A Boumendil, D Blaise, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Leukemia|January 5, 2013
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupC Fernández de Larrea, R A Kyle, B G M Durie, et al.
Leukemia|December 30, 2015
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working GroupJ Laubach, L Garderet, A Mahindra, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Bone Marrow Transplantation|September 22, 2019
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)E González-Barca, A Boumendil, D Blaise, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Leukemia|January 5, 2013
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupC Fernández de Larrea, R A Kyle, B G M Durie, et al.
Leukemia|December 30, 2015
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working GroupJ Laubach, L Garderet, A Mahindra, et al.
Pageof 6